Targeting the pathogenic role of interleukin 1β in the progression of smoldering/indolent myeloma to active disease

Mayo Clinic Proceedings

Volumn 84, Issue 2, 2009, Pages 105-107

  Dinarello, Charles A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DEXAMETHASONE; INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THALIDOMIDE; ANTINEOPLASTIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6;

ANTIBODY PRODUCTION; AUTOINFLAMMATORY DISEASE; CLINICAL TRIAL; DISEASE COURSE; EDITORIAL; HUMAN; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRECANCER; RHEUMATOID ARTHRITIS; BIOSYNTHESIS; NOTE;

ANTINEOPLASTIC AGENTS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; MULTIPLE MYELOMA;

EID: 61449148027     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.2.105     Document Type: Editorial

References (13)

1. Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin-6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84(2): .
2. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582-2590.
3. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol. 2009;27:519-550.
4. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2645-2650. Epub 2003 Feb 21.
5. Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am. 1999;13(6):1117-1125.
6. Donovan KA, Lacy MQ, Kline MP, et al. Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Leukemia. 1998;12(4):593-600.
7. Payette H, Roubenoff R, Jacques PF, et al. Insulin-like growth factor-1 and interleukin 6 predict sarcopenia in very old community-living men and women: the Framingham Heart Study. J Am Geriatr Soc. 2003;51(9):1237-1243.
8. Gu ZJ, De Vos J, Rebouissou C, et al. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia. 2000;14(1):188-197.
9. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. 1995;86(2):685-691.
10. Fisher CJ Jr, Slotman GJ, Opal SM, et al; IL-1RA Sepsis Syndrome Study Group. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994;22(1):12-21.
11. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med. 2006;355(6):581-592.
12. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58(8):2443-2452.
13. Donath M, Weder C, Whitemore J, et al. XOMA 052, an anti-IL-1β antibody, in a double-blind, placebo controlled, dose escalation study of the safety and pharmacokinetics in patients with type 2 diabetes mellitus - a new approach to therapy [abstract 1]. Diabetologia. 2008;51(suppl 1):S7.